More specifically, the differentiation of CD11b- and CD14-positive cells was accelerated by the combination of the two drugs, which ultimately contributed to apoptosis, thus allowing us to confirm that it was the differentiation capacity of dasatinib-potentiated VPA that induced AML cell apoptosis. This evidence concerns the gene CD14 and acute myeloid leukemia.